Dynavax Technologies Corporation - Common Stock (DVAX)
Frequently Asked Questions About Dynavax Technologies Corporation - Common Stock (DVAX)
Has Dynavax received any FDA approvals?
Yes, Dynavax received FDA approval for Heplisav-B in November 2017. This approval marked a significant milestone for the company and validated its innovative approach to vaccine development.
How has Dynavax performed in recent financial reports?
Dynavax's recent financial reports indicate varying performance metrics including revenue from sales of Heplisav-B, research and development expenses, and other operational costs. Investors are encouraged to review the latest earnings releases for detailed insights.
How is Dynavax funded?
Dynavax has been funded through a combination of public market offerings, private investments, and collaborations with other companies. The company has made efforts to raise capital to support its research and development initiatives.
Is Dynavax publicly traded?
Yes, Dynavax Technologies Corporation is publicly traded on the NASDAQ under the ticker symbol DVAX. As a publicly traded company, it is subject to regulatory requirements and disclosures.
What are the key technologies used by Dynavax?
Dynavax utilizes a unique proprietary technology platform that includes a novel approach to vaccine formulation and immunostimulation through the use of the adjuvant CpG 1018. This technology enhances the immune response to vaccines.
What are the risks involved in investing in Dynavax?
Investing in Dynavax involves risks such as the uncertainties of clinical development, regulatory approval processes, market competition, and the overall performance of the biopharmaceutical market. Potential investors should carefully consider these factors.
What collaborations does Dynavax have?
Dynavax has formed strategic collaborations with various organizations and institutions to advance its research and product development. These collaborations often involve partnerships for clinical trials and technology sharing.
What does Dynavax Technologies Corporation do?
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that focuses on the development of novel vaccines and immunotherapy products, particularly in the areas of infectious diseases and cancer. The company's pipeline includes its lead product, Heplisav-B, a hepatitis B vaccine that has been approved by the U.S. FDA.
What does Dynavax's pipeline look like?
Dynavax's pipeline includes Heplisav-B and several other vaccine candidates currently in various stage of development, which aim to target infectious diseases and conditions requiring enhanced immunotherapy.
What is Dynavax's approach to research and development?
Dynavax emphasizes a science-driven approach to research and development. The company invests heavily in exploring innovative immunotherapeutic concepts and enhancing vaccine efficacy through advanced technology platforms.
What is Dynavax's business model?
Dynavax's business model revolves around the development and commercialization of its proprietary products and technologies, partnerships with other companies for R&D, and leveraging its expertise in immunology to advance its pipeline.
What is Heplisav-B?
Heplisav-B is an FDA-approved vaccine developed by Dynavax for the prevention of hepatitis B in adults. It is notable for its two-dose regimen and has shown a strong immunogenic response and efficacy in clinical trials.
What is the company's vision for the future?
Dynavax's vision is to leverage its innovative technologies to develop groundbreaking vaccines and immunotherapy solutions that address significant unmet medical needs, ultimately enhancing human health and expanding vaccine access globally.
What is the significance of CpG 1018?
CpG 1018 is a synthetic oligodeoxynucleotide that acts as an adjuvant, enhancing the body's immune response to the antigens in vaccines. It is a key component of Heplisav-B and is being investigated in other vaccine candidates for improved efficacy.
What markets does Dynavax focus on?
Dynavax primarily focuses on the vaccine market, targeting infectious diseases, particularly hepatitis B, and the growing field of immunotherapy for cancer treatment. The company sees significant opportunities for growth in both domains.
What potential do analysts see in Dynavax?
Analysts often view Dynavax positively due to its innovative vaccine platform and potential for market growth, especially in the context of global health needs for effective vaccines. Growth estimates and opinions can vary based on market conditions.
When was Dynavax Technologies Corporation founded?
Dynavax Technologies Corporation was founded in 1996. Since its inception, the company has focused on advancing its proprietary technologies and developing treatments for infectious diseases and cancer.
Where is Dynavax Technologies Corporation located?
Dynavax Technologies Corporation is headquartered in Berkeley, California. The company operates in a vibrant biotech ecosystem that supports innovation and development in the pharmaceuticals and vaccine sectors.
Who are the key executives at Dynavax?
Key executives at Dynavax include CEO Ryan Spencer, who has extensive experience in the life sciences industry, as well as other specialists in fields such as research, development, and commercialization of pharmaceuticals.
What is the current price of Dynavax Technologies Corporation - Common Stock?
The current price of Dynavax Technologies Corporation - Common Stock is 12.87
When was Dynavax Technologies Corporation - Common Stock last traded?
The last trade of Dynavax Technologies Corporation - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Dynavax Technologies Corporation - Common Stock?
The market capitalization of Dynavax Technologies Corporation - Common Stock is 1.65B
How many shares of Dynavax Technologies Corporation - Common Stock are outstanding?
Dynavax Technologies Corporation - Common Stock has 128.49M shares outstanding.